RNC Pharma Database Update: Pharmaceutical Drug Production in Russia (June 2018)
Between January and June 2018, Russia produced 157.4 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms 1.2% lower than that of the same period of 2017. In physical terms, Russia produced 2 bln units of pharmaceuticals over the period, which is 10% lower than that of the same period of 2017. If calculated in minimum dosage units (MDU), the dynamics are +0.6%. The dynamics of the production of over-the-counter drugs in physical terms are -9%, while those of the Rx production are -11%. In June, the dynamics of the OTC production were +4.5%, while those of the Rx production were -19%.
Among the top 10 EphMRA groups of level two with the highest dispatch volume of OTC drugs in physical terms, 7 have negative dynamics. Antivirals, painkillers and cough and cold medicines are among the worst, with -32%, -19% and -15%, respectively. Nose medicines have the highest dynamics in the groups with a sales increase, especially Oxyfrin (Groteks) and Evamenol (Moscow Pharmaceutical Factory), with a 47% increase.
As for Rx drugs, the following categories have the lowest dynamics: solutions for intravenous admission (-50%), anti-infective drugs (-19%), and anti-inflammatory and anti-rheumatics drugs (-15%). Nevertheless, the production of beta-adrenoblockers has very good dynamics (+52%), in particular Sotalol (Canonpharma Production) (+100%) and Nebivolol (Severnaya Zvezda) (+56%.)
Read more about pharmaceutical drug production in Russia (April results) here: http://rncph.com/news/29_06_2018
Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2017 – June 2018)